SEC Comment Letter for Kaleido Biosciences, Inc. (KLDO) (CIK 0001751299) — Aug 12, 2020
Kaleido Biosciences, Inc. (KLDO) (CIK 0001751299)
Date: Aug. 12, 2020 · CIK: 0001751299 · Accession: 0000000000-20-007375
AI Filing Summary & Sentiment
File numbers found in text: 333-240323
Letter
United States securities and exchange commission logo August 12, 2020 William Duke, Jr. Chief Financial Officer Kaleido Biosciences, Inc. 65 Hayden Avenue Lexington, MA 02421 Re:Kaleido Biosciences, Inc. Registration Statement on Form S-3 Filed August 4, 2020 File No. 333-240323 Dear Mr. Duke: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at (202) 551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Laurie A. Burlingame
Show Raw Text
United States securities and exchange commission logo
August 12, 2020
William Duke, Jr.
Chief Financial Officer
Kaleido Biosciences, Inc.
65 Hayden Avenue
Lexington, MA 02421
Re:Kaleido Biosciences, Inc.
Registration Statement on Form S-3
Filed August 4, 2020
File No. 333-240323
Dear Mr. Duke:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at (202) 551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Laurie A. Burlingame